Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

CON vs ARDT: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CON Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 8–2 Matrix Metrics)

CON Overall Winner 6-Pillar Tally: CON 4 – 2 ARDT Matrix Metrics: CON 8 – 2 ARDT

As of Nov 20, 2026, Concentra Group Holdings Parent, Inc. (CON) is the stronger overall head-to-head candidate over Ardent Health, Inc. (ARDT) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). CON carries a Unified Composite Score of 43.5/100 (HOLD) at $41.84 (22.0x Forward P/E, 17.2% operating margin), whereas ARDT carries 40.2/100 (SELL) at $15.08 (10.9x Forward P/E, 5.1% operating margin).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CON vs ARDT
CON NYSE Head-to-Head Winner
Concentra Group Holdings Parent, Inc.
Services-Specialty Outpatient Facilities, Nec
$41.84
+0.94% 1D
Market Cap $5.2B
TTM Revenue $2.34B
Forward P/E 22.0x
Beta / 30D Vol 0.52β · 38% Vol
Unified Composite Score
43.5 / 100 HOLD
Tech 31.0 Fund 47.0 Flow 69.0 Mom 41.1
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (8.0% over 20 days), RSI 56
RSI-14: 55.6 · SMA20: $41.80 · SMA50: $38.66
ARDT NYSE
Ardent Health, Inc.
Services-General Medical & Surgical Hospitals, Nec
$15.08
+4.0% 1D
Market Cap $2.0B
TTM Revenue $6.45B
Forward P/E 10.9x
Beta / 30D Vol 0.01β · 115% Vol
Unified Composite Score
40.2 / 100 SELL
Tech 15.0 Fund 38.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (14.6% over 20 days), RSI 53
RSI-14: 52.8 · SMA20: $14.96 · SMA50: $12.65

6-Pillar Scorecard Institutional Category Breakdown (CON 4 – 2 ARDT)

Columns: Metric · CON · ARDT
1. Valuation Multiples ARDT
Forward P/E 22.0x 10.9x
Trailing P/E 24.5x 14.1x
PEG Ratio N/M N/M
EV / Revenue 3.1x 0.3x
2. Growth & Scale CON
Revenue Growth (YoY) +8.6% +3.1%
Earnings Growth (YoY) +36.4% -77.1%
TTM Revenue (USD) $2.34B $6.45B
Market Cap $5.2B $2.0B
3. Profitability & Quality CON
Gross Margin 29.9% 59.1%
Operating Margin 17.2% 5.1%
Net Profit Margin 9.3% 2.3%
Return on Equity (ROE) 47.2% 13.5%
4. Balance Sheet & Cash Flow CON
Cash Generation (TTM) $257M $494M EBITDA
Cash Flow Margin 11.0% 7.7% EBITDA Mgn
Net Cash / Leverage $2.04B Net Debt (4.20x D/E) $9.91 Book/Sh · 13.5% ROE
Dividend Yield 0.60% None (0.00%)
5. Options & Positioning CON
Options Structure Phase BREAKOUT UNCLASSIFIED
Current IV / %ile 269.9% (95th %ile) 53.1% (16th %ile)
Put/Call OI Skew 0.79x (Call-Skewed) N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Markup
6. R&D & Supply-Chain Moat ARDT
OpEx & R&D Intensity 12.7% of Rev ($297M) 54.0% of Rev ($3.49B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Care Facilities Operator Medical Care Facilities Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CON (8) vs ARDT (2)
Institutional Metric CON ARDT Criterion Row Edge
Market Capitalization
Scale
$5.2B $2.0B Larger Scale CON
Trailing P/E Ratio
Valuation
24.5x 14.1x Lower Multiple ARDT
Forward P/E Ratio
Valuation
22.0x 10.9x Lower Multiple ARDT
Revenue Growth (YoY)
Growth
+8.6% +3.1% Higher Growth CON
Operating Margin (TTM)
Profitability
17.2% 5.1% Higher Margin CON
Net Profit Margin
Profitability
9.3% 2.3% Higher Margin CON
Return on Equity (ROE)
Capital Efficiency
47.2% 13.5% Higher ROE CON
52-Week Range Position
Momentum
91% ($19–$44) 68% ($8–$19) Stronger Trend CON
Beta / 30D Volatility
Risk Regime
0.52β · 38% Vol 0.01β · 115% Vol Lower Realized Risk CON
Unified Institutional Score
Composite Signal
43.5 / 100 (HOLD) 40.2 / 100 (SELL) Higher Composite CON
Trailing 12M Revenue (USD)
Operating Scale
$2.34B $6.45B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
29.9% 59.1% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 3.1x EV/Rev N/M PEG · 0.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$257M ($2.04B Net Debt (4.20x D/E)) $494M EBITDA ($9.91 Book/Sh · 13.5% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ARDT +17.33 pp
CON: +4.68% · ARDT: +22.01%
3M Horizon ARDT +14.46 pp
CON: +19.58% · ARDT: +34.04%
6M Horizon CON +1.86 pp
CON: +65.24% · ARDT: +63.38%
1Y Horizon CON +42.84 pp
CON: +117.58% · ARDT: +74.74%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CON vs ARDT. Trailing 12-month operating profitability (CON 17.2% vs ARDT 5.1%) and valuation multiples (CON 22.0x vs ARDT 10.9x Forward P/E) are benchmarked directly in Pillar 4 below.

CON ADR TTM Benchmark FX-Normalized USD
TTM Revenue$2.34B
Gross Margin29.9%
Op. Margin17.2%
ROE / Fwd P/E47.2% · 22.0x
ARDT ADR TTM Benchmark FX-Normalized USD
TTM Revenue$6.45B
Gross Margin59.1%
Op. Margin5.1%
ROE / Fwd P/E13.5% · 10.9x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CON BREAKOUT
99d in phase · OBV NEUTRAL
Current IV 269.9%
IV Percentile 95th %ile
Put/Call OI Skew 0.79x (Call-Skewed)
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact CON Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ARDT UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 53.1%
IV Percentile 16th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ARDT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CON Moat Profile High-Margin Pricing Power Moat
Medical Care Facilities Operator
Competes within the Medical Care Facilities value chain with $5.2B market capitalization and 17.2% operating margin.
OpEx & R&D Reinvestment 12.7% of Rev ($297M)
90D Engineering Disclosures 0 Published
ARDT Moat Profile Cyclical / Execution-Driven Positioning
Medical Care Facilities Operator
Competes within the Medical Care Facilities value chain with $2.0B market capitalization and 5.1% operating margin.
OpEx & R&D Reinvestment 54.0% of Rev ($3.49B)
90D Engineering Disclosures 0 Published

Investor FAQ CON vs ARDT Key Questions & Quantitative Answers

As of Nov 20, 2026, Concentra Group Holdings Parent, Inc. (CON) is the stronger overall head-to-head candidate over Ardent Health, Inc. (ARDT) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). CON carries a Unified Composite Score of 43.5/100 (HOLD) at $41.84 (22.0x Forward P/E, 17.2% operating margin), whereas ARDT carries 40.2/100 (SELL) at $15.08 (10.9x Forward P/E, 5.1% operating margin). Technically, CON sits in a Markup phase (RSI 55.6, BREAKOUT options structure) and ARDT sits in a Markup phase (RSI 52.8, UNCLASSIFIED options structure).

CON leads the Growth & Scale pillar: CON posts +8.6% YoY revenue growth and +36.4% YoY earnings growth on $2.34B TTM revenue (29.9% gross margin, 17.2% operating margin), compared with ARDT at +3.1% YoY revenue growth and -77.1% YoY earnings growth on $6.45B TTM revenue (59.1% gross margin, 5.1% operating margin). On trailing 12-month operating scale, CON generates $2.34B in USD-normalized revenue versus $6.45B for ARDT. In operating R&D and SG&A reinvestment, CON deploys 12.7% of Rev ($297M) (0 90-day corporate R&D disclosures) versus 54.0% of Rev ($3.49B) (0 disclosures) for ARDT.

ARDT screens cheaper on headline valuation multiples. CON trades at 22.0x Forward P/E, 24.5x Trailing P/E, N/M PEG, and 3.1x EV/Revenue (11.0% FCF margin), whereas ARDT trades at 10.9x Forward P/E, 14.1x Trailing P/E, N/M PEG, and 0.3x EV/Revenue (7.7% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CON (47.2% ROE) versus ARDT (13.5% ROE) capital efficiency.

In options market volatility and institutional positioning, CON carries 269.9% implied volatility (95th %ile, Extreme (>80th %ile)), a 0.79x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKOUT options structure phase (0.52β · 38% Vol realized risk). By comparison, ARDT carries 53.1% implied volatility (16th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.01β · 115% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.